{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:06:19Z","timestamp":1789751179186,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008513","name":"Thomas Jefferson University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021763","name":"American Urological Association Education and Research, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urology.2026.07.036","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:09:15Z","timestamp":1785856155000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mortality in Medicare-aged Men With Metastatic Prostate Cancer After the Introduction of Androgen Receptor Pathway Inhibitors: A Population-based Study"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-8100","authenticated-orcid":false,"suffix":"Jr.","given":"Isaac E.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krupa","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Nikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Keith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Yi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lu-Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.07.036_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2026.07.036_bib2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.urology.2026.07.036_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2018.04.083","article-title":"Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens","volume":"200","author":"Crawford","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.07.036_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2026.07.036_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.urology.2026.07.036_bib6","doi-asserted-by":"crossref","first-page":"8147","DOI":"10.1158\/1078-0432.CCR-04-1402","article-title":"Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer","volume":"10","author":"Dagher","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2026.07.036_bib7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2026.07.036_bib8","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/pros.23064","article-title":"Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer","volume":"75","author":"Maughan","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2026.07.036_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/fon.13.275","article-title":"Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial","volume":"10","author":"Nadal","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.urology.2026.07.036_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2026.07.036_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40265-018-0900-z","article-title":"Apalutamide: first global approval","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.urology.2026.07.036_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1358\/dot.2020.56.3.3110574","article-title":"Darolutamide for treatment of castration-resistant prostate cancer","volume":"56","author":"Rhea","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.urology.2026.07.036_bib13","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2026.07.036_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.28485","article-title":"No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period","volume":"120","author":"Wu","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2026.07.036_bib15","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.1002\/cam4.4074","article-title":"Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era","volume":"10","author":"Kim","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.urology.2026.07.036_bib16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12350-014-9908-2","article-title":"Survival analysis and regression models","volume":"21","author":"George","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.urology.2026.07.036_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.urology.2026.07.036_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"key":"10.1016\/j.urology.2026.07.036_bib19","article-title":"The diagnostic role of (18)F-Choline, (18)F-Fluciclovine and (18)F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urology.2026.07.036_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.07.036_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","article-title":"Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry","volume":"15","author":"Chowdhury","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.urology.2026.07.036_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12894-022-00979-9","article-title":"Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan","volume":"22","author":"Leith","year":"2022","journal-title":"BMC Urol"},{"key":"10.1016\/j.urology.2026.07.036_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-020-00275-3","article-title":"Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses","volume":"24","author":"Lee","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2026.07.036_bib24","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1002\/cncr.33176","article-title":"Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer","volume":"126","author":"Caram","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2026.07.036_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhealeco.2017.01.005","article-title":"Did medicare part D reduce mortality?","volume":"53","author":"Huh","year":"2017","journal-title":"J Health Econ"},{"key":"10.1016\/j.urology.2026.07.036_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/UPJ.0000000000000421","article-title":"Out-of-pocket costs for prostate cancer medications substantially vary by medicare part D plan: an online tool presents an opportunity to mitigate financial toxicity","volume":"10","author":"Pockros","year":"2023","journal-title":"Urol Pract"},{"key":"10.1016\/j.urology.2026.07.036_bib27","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.3390\/cancers13143478","article-title":"Differential but concerted expression of HSD17B2, HSD17B3, SHBG and SRD5A1 testosterone tetrad modulate therapy response and susceptibility to disease relapse in patients with prostate cancer","volume":"13","author":"Bamodu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urology.2026.07.036_bib28","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JU.0000000000001568","article-title":"Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses","volume":"205","author":"Armstrong","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.07.036_bib29","first-page":"3","article-title":"Updated overview of the SEER-medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.urology.2026.07.036_bib30","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0022-510X(09)71300-0","article-title":"The Will Rogers phenomenon: the effect of different diagnostic criteria","volume":"287","author":"Sormani","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.urology.2026.07.036_bib31","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","article-title":"The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer","volume":"312","author":"Feinstein","year":"1985","journal-title":"N Engl J Med"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526004917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526004917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:15:47Z","timestamp":1789748147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526004917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S0090429526004917"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.07.036","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality in Medicare-aged Men With Metastatic Prostate Cancer After the Introduction of Androgen Receptor Pathway Inhibitors: A Population-based Study","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.07.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}